Cassady Schiller Wealth Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Cassady Schiller Wealth Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$779	Buy	+62	New	+$933	﹤0.01%	851

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cassady Schiller Wealth Management's RCKT Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Rocket Pharmaceuticals (RCKT) in Q4 2024: 62 shares worth $779. The stake represents ﹤0.01% of the portfolio and ranks #851 among its holdings.

225 funds tracked by Wall St. Rank hold RCKT as of Q4 2024.

Cassady Schiller Wealth Management held 62 shares of Rocket Pharmaceuticals worth $779 as of Q4 2024.
Rocket Pharmaceuticals was a new Cassady Schiller Wealth Management position in Q4 2024.
Rocket Pharmaceuticals made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #851 holding.
225 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.